Phase-II Study of Olaparib as Maintenance Therapy After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms OLATRA
- 09 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 New trial record